Trademark Attorney / Law Firm

Edward J. Adamson – Trademark Portfolio

Edward J. Adamson specializes in Class 5 (Pharmaceuticals) trademark filings before the United States Patent and Trademark Office (USPTO), with 11 of 11 total filings concentrated in this category. Filing activity spans from 2006 to 2009. Currently, 0 trademarks are registered.

11 Total Trademarks
Loading...
By Date
By Name
Filter by Class:

CELTX
CELTX
Abandoned 2011
PROTX
PROTX
Abandoned 2011
VERCUTX
VERCUTX
Abandoned 2011
REVITX
REVITX
Abandoned 2011
REVITIX
REVITIX
Abandoned 2011
VERCUTIS
VERCUTIS
Abandoned 2011
PROTX
PROTX
Abandoned 2009
VERCUTX
VERCUTX
Abandoned 2009
REVITIX
REVITIX
Abandoned 2009
REVITX
REVITX
Abandoned 2009
CELTX
CELTX
Abandoned 2006

Practice Areas by Trademark Class

Edward J. Adamson's trademark practice covers 1 Nice Classification class, representing the range of industries and goods/services handled in their USPTO filings.

5
Pharmaceuticals (11 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademark applications has Edward J. Adamson filed?

Edward J. Adamson has filed 11 trademark applications with the United States Patent and Trademark Office (USPTO).

What trademark classes does Edward J. Adamson specialize in?

Edward J. Adamson has filed trademarks across 1 Nice Classification class. The most common practice areas include Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

How long has Edward J. Adamson been filing trademarks?

Edward J. Adamson's trademark filing history with the USPTO spans from 2006 to 2009, covering 3 years of trademark practice. During this period, Edward J. Adamson has handled 11 trademark applications.

What is Edward J. Adamson's trademark registration success rate?

Edward J. Adamson has a 0% trademark registration rate, with 0 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.